ARCUTIS BIOTHERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $13.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $13.07M, a 21.99% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.87M, a 9.60% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $10.24M, a 2.75% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.72M, a 14.42% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $41.14M, a 3.70% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $42.72M, a 10.07% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $38.81M, a 18.76% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $32.68M, a 36.79% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.07M 10-Q · filed 2026-08-05 | $23.94M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $10.87M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $41.14M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $10.24M 10-Q · filed 2025-10-28 | $20.96M derived: sum of 2 quarters · filed 2026-08-05 | $30.87M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $10.72M 10-Q · filed 2026-08-05 | $20.63M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $9.91M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $42.72M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $10.53M 10-Q · filed 2025-10-28 | $23.05M derived: sum of 2 quarters · filed 2025-10-28 | $33.08M derived: sum of 3 quarters · filed 2025-10-28 | |
| 2024-06-30 | $12.52M 10-Q · filed 2025-10-28 | $22.55M derived: sum of 2 quarters · filed 2025-10-28 | ||
| 2024-03-31 | $10.03M 10-Q · filed 2025-10-28 | |||
| 2023-12-31 | $38.81M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $10.00M 10-Q · filed 2024-11-06 | $20.58M derived: sum of 2 quarters · filed 2024-11-06 | $30.06M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $10.58M 10-Q · filed 2024-11-06 | $20.06M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $9.48M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $32.68M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $8.79M 10-Q · filed 2023-11-03 | $16.89M derived: sum of 2 quarters · filed 2023-11-03 | $23.42M derived: sum of 3 quarters · filed 2023-11-03 | |
| 2022-06-30 | $8.10M 10-Q · filed 2023-11-03 | $14.63M derived: sum of 2 quarters · filed 2023-11-03 | ||
| 2022-03-31 | $6.53M 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | $23.89M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $5.36M 10-Q · filed 2022-11-08 | $9.70M derived: sum of 2 quarters · filed 2022-11-08 | $18.21M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $4.34M 10-Q · filed 2022-11-08 | $12.84M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $8.50M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $7.94M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $2.26M 10-Q · filed 2021-11-04 | $4.31M derived: sum of 2 quarters · filed 2021-11-04 | $5.30M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $2.05M 10-Q · filed 2021-11-04 | $3.04M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $990.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $824.00K 10-K · filed 2022-02-22 | |||
| 2019-09-30 | $154.00K 10-Q · filed 2020-11-05 | $293.00K derived: sum of 2 quarters · filed 2020-11-05 | $369.00K derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $139.00K 10-Q · filed 2020-11-05 | $215.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $76.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $151.00K 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |